RNF2 has also been found to be highly expressed in large series of cancer types including breast cancer, ovarian cancer, pancreatic cancer, bladder cancer, melanoma, lymphoma, et al. And high expression of RNF2 is positively correlated with tumor progression and shortened survival, thus RNF2 is considered to be a prognostic biomarker and potential therapeutic target for these cancer types [19–22]. Here, RNF2 is linked to ovarian cancer.